Concept
Addressing Anti-Ad5 immunity in the Ad5 vectored COVID-19 Vaccine
- In some people with high pre-existing immunity, the dosage Zhu and colleagues determined to be more safe, (5.0X10^10 viral particles) may not be strong enough to induce an immune response
- Older people are more likely to have been exposed to Ad5, and therefore are more likely to tolerate a higher dosage of the vaccine than younger people who have not been previously exposed to Ad5.
- From the researchers’ previous experience with the Ad5 vector based Ebola vaccine, they found that an additional dose 3 to 6 months after the primary dose may be a good solution for anti-Ad5 immunity.
0
1
Updated 2020-10-09
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences